ReviewMolecular neurobiology2020
Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics.
Review in Molecular neurobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05081271 (COVID-19 Booster Vaccination in Persons With Multiple Sclerosis), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
Who cites it
29 citing papers in PubMed.
- COVID-19 management in patients with comorbid conditions.World journal of virology · 2025Review
- Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.Cell communication and signaling : CCS · 2023Review
- Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?Antioxidants & redox signaling · 2023Review
- An overview on the treatments and prevention against COVID-19.Virology journal · 2023Review
- Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.International journal of pharmaceutics · 2022Review
- 'A disease like any other' traditional, complementary and alternative medicine use and perspectives in the context of COVID-19 among the Congolese community in Belgium.Journal of ethnobiology and ethnomedicine · 2022Article
- Healthy Immunity on Preventive Medicine for Combating COVID-19.Nutrients · 2022Review
- In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase.Molecular diversity · 2022Article
- Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review.Therapeutic advances in vaccines and immunotherapy · 2022Review
- COVID-19 and its genomic variants: Molecular pathogenesis and therapeutic interventions.EXCLI journal · 2022Review
- Molecular docking, molecular dynamics simulation, and ADMET analysis of levamisole derivatives against the SARS-CoV-2 main protease (MBioImpacts : BI · 2022Article
- Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?Molecular biomedicine · 2021Review
- Exploration ofChemical physics · 2021Article
- GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Computational studies reveal Fluorine based quinolines to be potent inhibitors for proteins involved in SARS-CoV-2 assembly.Journal of fluorine chemistry · 2021Article
- Chemotherapy vs. Immunotherapy in combating nCOVID19: An update.Human immunology · 2021Review
- Article
- Plant-Based Phytochemical Screening by Targeting Main Protease of SARS-CoV-2 to Design Effective Potent Inhibitors.Biology · 2021Article
- Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection.Clinical microbiology reviews · 2021Review
- Vaccination in the Philippines: experiences from history and lessons for the future.Human vaccines & immunotherapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The coronavirus disease of 2019 (COVID-19) is a pandemic disease that has taken the lives of many around the world. It is caused by severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2). To date, the USA, Italy, Spain, France, Russia, and the UK have been hit the hardest by the virus. However, death counts are still rising. Some nations have managed to "flatten" the death rate via protective measures such physical distancing, quarantine measures, and therapeutic management. The structure of the SARS-CoV-2 virus comprises of S proteins, M proteins, E proteins, hemagglutinin esterases, nucleocapsid proteins, and a 30-kb RNA genome. Viral proteases cleave these polyproteins and RNA-dependent polymerases replicate the genome. Currently, there are no effective therapies against this new disease. Numerous investigators are developing novel protease inhibitors, some of which have made it into clinical trials. Researchers are also attempting to develop a vaccine. In this review paper, we discuss the latest therapeutic developments against COVID-19. Graphical Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.